

Annapaola Prestia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7124603/publications.pdf>

Version: 2024-02-01

21
papers

1,319
citations

516215

16
h-index

713013

21
g-index

21
all docs

21
docs citations

21
times ranked

2610
citing authors

#	ARTICLE	IF	CITATIONS
1	A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia. <i>Neuroinformatics</i> , 2014, 12, 575-593.	1.5	240
2	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , 2013, 80, 1048-1056.	1.5	161
3	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). <i>Neurology</i> , 2015, 84, 508-515.	1.5	122
4	In vivo mapping of incremental cortical atrophy from incipient to overt Alzheimer's disease. <i>Journal of Neurology</i> , 2009, 256, 916-924.	1.8	116
5	Resting EEG sources correlate with attentional span in mild cognitive impairment and Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2007, 25, 3742-3757.	1.2	101
6	Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 556-570.	1.5	93
7	Markers of Alzheimer's disease in a population attending a memory clinic. <i>Alzheimer's and Dementia</i> , 2009, 5, 307-317.	0.4	80
8	Summary Metrics to Assess Alzheimer Disease-Related Hypometabolic Pattern with ¹⁸ F-FDG PET: Head-to-Head Comparison. <i>Journal of Nuclear Medicine</i> , 2012, 53, 592-600.	2.8	79
9	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , 2015, 11, 1191-1201.	0.4	71
10	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. <i>Alzheimer's and Dementia</i> , 2013, 9, 677-686.	0.4	51
11	Hippocampal and amygdalar volume changes in elderly patients with Alzheimer's disease and schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2011, 192, 77-83.	0.9	38
12	Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. <i>Electrophoresis</i> , 2012, 33, 3738-3744.	1.3	34
13	Alzheimer's CSF markers in older schizophrenia patients. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 640-648.	1.3	27
14	Hippocampal and Amygdalar Local Structural Differences in Elderly Patients with Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 47-58.	0.6	19
15	In Vivo Neuropathology of Cortical Changes in Elderly Persons with Schizophrenia. <i>Biological Psychiatry</i> , 2009, 66, 578-585.	0.7	18
16	Cortical Changes in Incipient Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1339-1349.	1.2	18
17	Validation Study of the Three-Objects-Three-Places Test: A Screening Test for Alzheimer's Disease. <i>Experimental Aging Research</i> , 2006, 32, 395-410.	0.6	14
18	Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 101-109.	0.6	14

#	ARTICLE	IF	CITATIONS
19	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	1.8	11
20	The in vivo topography of cortical changes in healthy aging and prodromal Alzheimer's disease. Supplements To Clinical Neurophysiology, 2013, 62, 67-80.	2.1	8
21	Alzheimer's disease and schizophrenia: evidence of a specific, shared molecular background. Future Neurology, 2011, 6, 17-21.	0.9	4